Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Dividend-focused pitch highlights Sanofi (down ~12% YTD; new ~52-week low near $41) with ~5.7% dividend yield and ~19x trailing earnings, despite Dupixent growing ~31% YoY. AT&T (down ~17% YTD) is framed as an undervalued dividend option at ~5.3% yield and ~7x P/E, while Vici Properties (6.7% yield; new 52-week low) reports quarterly FFO/share of $0.82 vs $0.51 prior year, with dividend of ~$0.45 covered. Overall, the article argues market selling has created “margin of safety” entry points in these income names rather than near-term fundamental deterioration.

Analysis

The market is treating all three as “yield stories,” but the underwriting quality is very different. SNY looks like a cash-compounding pharma with a long-dated patent issue that is already visible, while T is a classic value trap risk because the multiple reflects not just low growth but the possibility of structural share loss in a low-ARPU business. VICI sits in between: the dividend looks covered, but the real variable is tenant credit and refinancing conditions, not today’s occupancy print.

For SNY, the key is that a 2031 cliff is not an earnings event this year; the stock can rerate for 6-18 months if the pipeline keeps substituting for future loss of exclusivity. The market is underappreciating how much optionality a large-cap pharma gets when it can fund BD/R&D from current FCF, especially versus smaller biotech names that need external capital.

For T, the first-order damage from satellite competition may be limited, but the second-order effect is more important: any credible alternative to terrestrial connectivity compresses pricing power and raises the hurdle for long-duration growth investors. That means the stock can stay cheap for years unless management proves subscriber stability and ARPU resilience. VICI’s upside is more macro: lower rates would expand the multiple quickly, but if rates stay high, the dividend may still be fine while the equity stays range-bound.

Contrarian view: the consensus may be too bearish on SNY and too complacent that T’s low P/E equals safety. The real mispricing is that T’s valuation can be cheap for a reason, whereas SNY’s yield is being offered by a business with more visible earnings power and a longer runway before the patent story matters.

Key Decisions for Investors

• Long SNY on weakness over the next 1-3 months; prefer adding near current lows rather than chasing strength. Base case is a 6-18 month rerating if pipeline execution stays intact, with downside mainly if Dupixent growth decelerates sharply or phase 3 readouts disappoint.
• Pair trade: long SNY / short T for a 3-6 month relative-value expression. The spread should work if investors continue paying up for durable pharma cash flows while telecom remains capped by secular pricing pressure; thesis breaks if T shows clear evidence that Starlink competition is economically immaterial.
• Hold or initiate VICI as an income-plus-rate-cut trade over 6-12 months, but size modestly. Best upside comes from falling real rates and multiple expansion; key risk is tenant leverage/refinancing stress if consumer spending weakens or gaming operators need capital.
• Avoid initiating fresh longs in T until there is hard evidence on postpaid churn, ARPU, and any Starlink mobile rollout metrics. If management commentary confirms no near-term disruption, T can work as a defensive yield, but absent that, the asymmetric risk is to the downside.